Mostafa Moin, M.D.
Editor in Chief:
Mohammad Bagher Eslami, PhD.
Shahnaz Rafiei Tehrani, M.D., Ph.D.
The Iranian Journal of Allergy, Asthma and Immunology (IJAAI), an international peer-reviewed scientific and research journal, seeks to publish original papers, selected review articles, case-based reviews, and other articles of special interest related to the fields of asthma, allergy and immunology. The journal is an official publication of the Iranian Society of Asthma and Allergy (ISAA), which is supported by the Immunology, Asthma and Allergy Research Institute (IAARI) and published by Tehran University of Medical Sciences (TUMS). The journal seeks to provide its readers with the highest quality materials published through a process of careful peer reviews and editorial comments. All papers are published in English.
The IJAAI uses the World Association of Medical Editors’ definition of editorial freedom and is a member of the Committee on Publication Ethics (COPE). The journal adopts COPE’s guidelines upon encounter with ethical misbehavior.
Authors are requested to submit their manuscripts online at http://ijaai.tums.ac.ir. The system assigns a number to manuscripts and authors are requested to mention the manuscript number on all correspondence with the journal.
The Instructions to Authors of this journal are in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org).
The corresponding author and all other authors of the manuscript should sign under their own names in the cover letter before submitting the manuscript to this journal for publication. Corresponding author should enter all authors’ names, affiliations and emails in “Metadata” section while submitting the manuscript. Personal contact of corresponding author or the first author of the manuscript including the work phone number as well as a cell phone (mobile) number should be written in the cover letter and/or the title page of the manuscript.
This online manuscript submission and review system offers authors the option to track the progress of the review process of manuscripts in real time. The average turn-around times before you receive the first decision in this journal is approximately 8 weeks. In case you encounter any difficulties while submitting your manuscript online, please contact the editorial office (E-mail: email@example.com).
Manuscripts should be typed single-spaced with one-inch margins and Times New Roman, 12-point font size. All tables, figure legends, and references, must be typewritten with single spacing. All submitted components of the manuscript are non-returnable, unless a special arrangement is made in advance with the Editors. Arrange the manuscript with the following components: (1) Title page, (2) Abstract, (3) Introduction, (4) Materials/Patients and Methods,(5) Results, (6) Discussion, (7) Acknowledgements, (8) Conflict of Interest , (9) References, (10) Tables, and Figures and Figure Legends. Please place all illustrations, figures, and tables within the text at the appropriate points. It is also mandatory to upload the files of figures and tables separately as supplementary file (s) in a high resolution (JPEG or TIFF) format.
Authors should number all pages of the manuscript consecutively, beginning with the title page.
In addition, the editor requires authors to provide a cover letter in which they specifically state their written assurance of the following:
(1) The submitted paper is an original and unpublished work in which the listed authors have all made important contributions explaining the contributions in detail;
(2) The authors have not submitted the same material or portions thereof for consideration of publication in any other journal for which a decision regarding publication is pending, and no such additional submission will be made before completion of the review process by the IJAAI;
(3) The authors must further guarantee that, once their material has been accepted for publication by the journal, they will not make submission of the same material or portions thereof to another journal.
The editors also require that the authors be responsible for the linguistic and grammatical editing of manuscripts before submission to the journal. Only minor editing of the manuscript may be undertaken by the editor. All authors should adhere to the following instructions for submission of manuscripts to the IJAAI.
The authors should provide the assurances listed above. The authors must always make a complete statement to the editor about all previous reports and submissions that might be regarded as redundant or duplicate publications (including meeting presentations, registries, etc). If redundant or duplicate publication is attempted without notification, prompt rejection of the manuscript should be expected. In addition, authors are welcome to suggest three to five referees for their paper; however, the editors cannot guarantee assignment of a particular reviewer to a paper. Authors can provide editors with the names of persons they feel should not be asked to review a manuscript because of potential, usually professional, conflict of interest. Any unusual circumstances surrounding the research or explanations for deviation from standard procedures or format should be explained in the cover letter.
The corresponding author and all other authors of the manuscript should sign under their own names in the cover letter. Cover letter is mandatory to be uploaded as a supplementary file during the submission; otherwise the manuscript will be fast rejected. The authors are required to submit an ethics committee approval letter as a supplementary file and write the number of the approval letter in the cover letter and the acknowledgment section of the manuscript.
When using abbreviations, write the full name of the abbreviated item followed by the abbreviation in parentheses at the point of first mention within the abstract and the body of the manuscript: e.g., "cell mediated immunity (CMI)". Do not use abbreviations in the title of the manuscript. Abbreviations may be used in figures and tables, but such abbreviations must be explained in the figure legend or a footnote to the table unless the abbreviation is a standard unit of measurement.
The title page should contain the following information: (1) The full title of the manuscript, not to exceed 120 characters. No abbreviations are acceptable in the full title. If the work involves the use of an experimental model, the animal species involved must be included in the title. (2) The full names of all authors. Authorship credit should be based on a) substantial contributions to the conception or design, or the acquisition, analysis, or interpretation of data for the work; b) drafting the article or revising it critically for important intellectual content; and c) final approval of the version to be published; and d) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet conditions a, b, c and d. (3) The department and institution where work was performed, as well as the affiliations of the individual authors (more than 2 affiliations are not accepted for each author). (4) Source(s) of support, indicating any grants, equipments, drugs, or all of these for the study. (5) The name and address of the author responsible for correspondence. Include the name, mailing address, telephone and fax numbers, and e-mail address. (6) A shortened version of the title that is 45 characters or less to be used as a running title. (7) Word counts for the text only, excluding abstract, acknowledgements, figures, figure legends, tables and references. (8) The number of figures and tables should be noted on the title page.
Scientific articles should conform to the usual structure of abstract, introduction, materials/patients and methods, results, discussion, acknowledgements, conflict of interest, references, tables, figures and the legends. Number the pages starting with the title page. The text of original articles amounting to maximum 3000 words (excluding Abstract, References, Figures and Tables) should include Title; Abstract; Introduction; Materials & Methods; Results; Discussion; Conclusion; Acknowledgement; References, Tables and Figures (Not more than 4500 words).
The abstract must be limited to 250 words. Do not use footnotes or references in the body of
the abstract. Include a brief description of the goal, materials and methods, findings, and conclusion
of the study. Abstracts of clinical trials should include items that CONSORT group has identified as essential (http://www.consort-statement.org/?=1190).
Three to nine keywords for indexing should be given by the author(s) together with the abstract. They should be placed in alphabetical order and, when possible, adjusted to the medical subject headings (MESH) at http://www.nlm.nih.gov/mesh/.
Introduction, Materials/Patients and Methods, Results, and Discussion
Introduction: containing the reasons for doing the work and specific purpose or research objective; Methods: sufficient information must be included to permit reproduction of experimental work. Patients and Methods are used in the clinical sciences articles and Materials and Methods are used in the basic and laboratory sciences articles; Results: data and findings of research which should be given concisely; the use of tables and figures are encouraged but should not replicate the data presented in the text; Discussion: should not repeat results.
Include within the methods, a description of the ethical guidelines that were followed for human and animal studies. If appropriate, provide citation of institutional review by human or animal research committees. Also describe any hazardous procedures or chemicals involved in the studies and what precautions were taken to avoid injury to subjects or investigators. Within the Methods section, provide a brief but complete description of the statistical methods used including which tests were used for analysis of which variables. Specify the computer software used. Drugs, medication, or other material should be listed as generic items. If brand names are used, they should be placed after the generic name in parenthesis with the manufacturer's name, city, and state or country. Restrict all comments and discussion to the Discussion section.
All contributions that do not meet authorship criteria should be listed in acknowledgements section. Sources of financial support should be mentioned in this section, if required. The organization(s) which financially and otherwise supported the research project should be acknowledged, in order of priority (if necessary). The code number of ethics committee approval letter should be written in the acknowledgment.
Conflict of Interest
Conflict of interest should be mentioned or ruled out.
The IJAAI has now adopted the Vancouver Reference System and all submitted manuscripts should be in this style.
Cite references in text in order of appearance using Arabic numerals in parentheses for citations. Place the reference list at the end of the final text page. References should be listed in text citation number order and must be single-spaced. List all authors when six or fewer; when seven or more, list the first six and add “et al”. All published materials, including brief communications and letters to the editor must be cited in the References section.
Manuscripts accepted but not yet published can also be included in the references; designate the journal followed by 'in press' (in parentheses). References to unpublished material, such as personal communications and unpublished data, must be placed within the text and not cited in the Reference section. Personal communication and unpublished data must include the individual's name, location, and month and year of communication as appropriate. Use Index Medicusabbreviations for journals that are indexed; if a journal is not indexed, use full name. If using reference managing software such as Reference Manager, EndNote, or ProCite, choose the style for “Vancouver style” which most closely approximates our style. Please include volume, number and page range whenever possible.
* Saghafi S, Pourpak Z, Glocker C, Nussbaumer F, Babamahmoodi A, Grimbacher B, et al. The Diagnosis of Hyper Immunoglobulin E Syndrome Based on Project Management. Iranian Journal of Allergy Asthma and Immunology. 2015; 14(2):126-132.
* Nwaru BI, Hickstein L, Panesar S, Muraro A, Werfel T, Cardona V, et al. The epidemiology of food allergy in Europe: a systematic review and meta‐analysis. Allergy. 2014; 69(1):62-75.
Kirk Osterlan C, Farhoudi A. Assessment of immunodeficiency. In: Nakamura RM, Burek CL, Cook L, Folds JD, Server JL, editors. Clinical diagnostic immunology: Protocols in quality assurance and standardization. USA: Blackwell Science Pty Ltd, 1998: 197-208.
Each table should be typewritten with single spacing and numbered in order of citation in the text with Arabic numerals. Each table should have a concise heading that makes it comprehensible without reference to the text of the article. Use horizontal lines only at the top and bottom of the table and between column headings and the body of the table. Use no vertical lines. Explain any abbreviations in a footnote to the table.
Figures and Figure Legends
Figures must be submitted as electronic files in a format (for example, JPEG or TIFF) that will produce high-resolution images in the web version of the journal. The editors and publisher reserve the right to reject illustrations or figures based upon poor quality of submitted materials.
Figure legends should be typed using single spacing with explanations for symbols, arrows, or letters used to identify parts of illustrations. Explain any abbreviations in figure legends.
Brief Communications will be considered for publication on an accelerated schedule. It should have an abstract up to 250 words, a main body of maximum 2000 words including the Introduction, Methods, Results, Discussion, Conclusion; Acknowledgement, References, Tables and Figures. Maximum two figures and/or tables are acceptable (totally no more than 3000 words).
The Journal welcomes review articles covering basic or clinical allergy, asthma, and immunology that are likely to be of interest to the broad readership of the journal. For narrative review articles, at least one of the authors (especially the corresponding author) should be expert on the subject with related articles presented in the reference section. Review articles should include a section describing the methods of selecting, extracting and synthesizing data, which are also summarized in the abstract.
Systematic reviews and meta-analysis are also welcomed and they should follow the PRISMA (http://www.prisma-statement.org/) guideline. Review articles must include an abstract of no more than 250 words, a main text between 2500-3500 words excluding up to 90 references, tables and/or figures (altogether 5500-6000 words).
Short reports of clinical interest and brief individual case reports are welcome but only accepted in a limited number.
Letters to the Editor
Letters of opinion about articles published in the IJAAI and other current topics or short reports of clinical or laboratory interest are accepted for consideration for publication. These should not exceed 1000 words and 15 references and one table and/or figure with or without an abstract and subheadings. The editor reserves the right to edit such letters and to use his discretion in their selection for publication.
Ethics and Consent
Authors must state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki in 1995 (as revised in Edinburgh 2000).
The clinicians, who conduct a clinical trial on human subjects and wish to publish the results of their investigations in this journal, should have obtained permission for their clinical trial from Iranian Registry of Clinical Trials (IRCT) or other well-known clinical trials registries. IRCT number is mandatory for researches performed in Iran.
All studied subjects should be completely informed about the procedure and informed consent should be obtained from all participants. The journal reserves the right to request the related documents.
Revision of Manuscripts
Revisions must be submitted electronically only through the manuscript submission system at http://ijaai.tums.ac.ir(“Author version” section).
Revisions must include the responses to comments and also a marked revised manuscript. Our preferred method of showing changes is Microsoft Word's Track Changes feature. Alternately, added text should be underlined or highlighted, and any text that was deleted should be indicated by strikethrough formatting.
The Agreement is made with the IJAAI. The Agreement is for the article submitted by authors for publication in the IJAAI.
To enable publishing the article in the journal, the ownership of copyright must be established. The authors should read and complete the form and upload it on the website as a supplementary file. There are explanatory notes to this Agreement, which also form part of the Agreement.
In consideration of the publication of the article in the journal, authors warrant and undertake:
Note: The manuscript cannot be processed for publication until the publisher has received this signed form. If the manuscript is not published by the IJAAI, this letter will not take effect.
Proofs will be sent to the author and should be returned within 72 hours of receipt, preferably by the website. Corrections should be restricted to typesetting errors. The publisher will do everything quickly and accurately as possible. Therefore, it is important to ensure that all of your corrections are returned to us in one all-inclusive e-mail. Subsequent additional corrections will not be possible, so please ensure that your first communication is complete. The returned proof is your formal confirmation to publish the paper. Metadata of papers should be checked by the corresponding author at this stage
Fast Track Review of Papers
In the handling of all manuscripts for publication, the editors will strive to provide the most rapid turnaround possible in the review process. Authors may request rapid review of material felt to be of critical importance to the field. The request must state clearly why the authors believe rapid review is warranted and must be submitted to the editors in written form at the time of manuscript submission. Manuscripts accepted by the editors for rapid review might be published in the next scheduled issue of the journal or at the editors' discretion. Manuscripts submitted for rapid communication that require extensive revision will be rejected and the authors can resubmit the articles for regular publication. The journal requests authors for an extra charge for fast-track review of their papers. The requests can be sent by email to the editorial office.
According to the new policy of IJAAI, corresponding authors are requested to pay the article processing and publication charge as mentioned on the home page of the website (for Iranian authors).
In order to subscribe for hard copies, please contact journal office for subscription rates and processes.
Article Removal (authors’ withdrawal):
In case of any special considerations including ethical problems, editor-in-chief might decide to withdraw a paper and in that case, reasons for withdrawing the manuscript will be published on the journal’s website. If authors decide to remove their paper from journal’s online database, corresponding author should send a request signed by all authors explaining the reasons and the request for article removal. The journal will be sent a withdrawal acceptance letter to all authors.
Submission Preparation Checklist
As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
Mostafa Moin, M.D.
Editor in Chief:
Mohammad Bagher Eslami, PhD.
Shahnaz Rafiei Tehrani, M.D., Ph.D.
|This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.|